

Elizabeth R Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9233689/publications.pdf>

Version: 2024-02-01

49
papers

2,647
citations

430874
18
h-index

214800
47
g-index

52
all docs

52
docs citations

52
times ranked

3624
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State. <i>Clinical Infectious Diseases</i> , 2022, 74, 1089-1092. | 5.8 | 38 |
| 2 | Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization. <i>Aids</i> , 2022, 36, 257-265. | 2.2 | 6 |
| 3 | Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057. | 27.0 | 418 |
| 4 | Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission. <i>Journal of Infectious Diseases</i> , 2022, 226, 225-235. | 4.0 | 4 |
| 5 | Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. <i>JAMA Network Open</i> , 2022, 5, e2142796. | 5.9 | 57 |
| 6 | Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, , . | 5.8 | 0 |
| 7 | Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples. <i>Journal of Infectious Diseases</i> , 2022, , . | 4.0 | 4 |
| 8 | Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials. <i>JAMA Network Open</i> , 2022, 5, e2148325. | 5.9 | 24 |
| 9 | COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124. | 0.9 | 25 |
| 10 | Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, . | 2.1 | 1 |
| 11 | Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. <i>Cell Reports Medicine</i> , 2022, 3, 100679. | 6.5 | 100 |
| 12 | Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 513-520. | 5.8 | 22 |
| 13 | Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228. | 3.9 | 86 |
| 14 | Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Annals of Internal Medicine</i> , 2021, 174, 344-352. | 3.9 | 73 |
| 15 | Spatially Weighted Coronary Artery Calcium Score and Coronary Heart Disease Events in the Multi-Ethnic Study of Atherosclerosis. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e011981. | 2.6 | 16 |
| 16 | Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV</i> , 2021, 8, e87-e95. | 4.7 | 70 |
| 17 | Vaccine optimization for COVID-19: Who to vaccinate first?. <i>Science Advances</i> , 2021, 7, . | 10.3 | 305 |
| 18 | Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial. <i>AIDS and Behavior</i> , 2021, 25, 2430-2440. | 2.7 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence. <i>AIDS and Behavior</i> , 2021, 25, 4169-4179. | 2.7 | 5 |
| 20 | Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2801-2814. | 2.7 | 5 |
| 21 | Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 46. | 7.4 | 162 |
| 22 | A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026). <i>AIDS Research and Human Retroviruses</i> , 2021, , . | 1.1 | 5 |
| 23 | Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921. | 3.3 | 10 |
| 24 | Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE) Tj ETQq0 0.0rgBT /Overlock 10 | 1.6 | 23 |
| 25 | Implementation of a fully remote randomized clinical trial with cardiac monitoring. <i>Communications Medicine</i> , 2021, 1, . | 4.2 | 4 |
| 26 | Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 197-201. | 2.1 | 10 |
| 27 | Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. <i>Aids</i> , 2020, 34, 559-567. | 2.2 | 3 |
| 28 | Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities. <i>Statistics in Biosciences</i> , 2020, 12, 468-494. | 1.2 | 5 |
| 29 | Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIVâ€1 acquisition: a secondary analysis from a randomized, placeboâ€controlled trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25634. | 3.0 | 49 |
| 30 | Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 475. | 1.6 | 26 |
| 31 | Joint modeling of time-varying HIV exposure and infection for estimation of per-act efficacy in HIV prevention trials. <i>Statistical Communications in Infectious Diseases</i> , 2020, 12, . | 0.2 | 0 |
| 32 | Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. <i>Lancet HIV,the</i> , 2019, 6, e475-e482. | 4.7 | 19 |
| 33 | Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial. <i>AJOB Empirical Bioethics</i> , 2019, 10, 79-87. | 1.6 | 3 |
| 34 | O03.6â€...Vaginal bacteria and risk of incident and persistent infection with high risk sub-types of human papillomavirus. , 2019, , . | | 0 |
| 35 | Crossover and Repeated Randomization in Event Driven Trials for HIV Prevention: Addressing the Impact of Heterogeneity in Risk in the Trial Design. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, . | 0.2 | 1 |
| 36 | Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. <i>HIV Clinical Trials</i> , 2018, 19, 8-14. | 2.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, e8-e10. | 2.1 | 19 |
| 38 | Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 330-337. | 2.1 | 16 |
| 39 | Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 73, 606-608. | 2.1 | 81 |
| 40 | Estimating effectiveness in HIV prevention trials with a Bayesian hierarchical compound Poisson frailty model. <i>Statistics in Medicine</i> , 2016, 35, 2609-2634. | 1.6 | 6 |
| 41 | Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132. | 27.0 | 624 |
| 42 | Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. <i>Contraception</i> , 2016, 93, 25-31. | 1.5 | 15 |
| 43 | Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 335-342. | 4.0 | 40 |
| 44 | Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. <i>PLoS ONE</i> , 2015, 10, e0128857. | 2.5 | 25 |
| 45 | High Incidence Is Not High Exposure: What Proportion of Prevention Trial Participants Are Exposed to HIV?. <i>PLoS ONE</i> , 2015, 10, e0115528. | 2.5 | 8 |
| 46 | Estimating the effectiveness in HIV prevention trials by incorporating the exposure process: Application to HPTN 035 data. <i>Biometrics</i> , 2014, 70, 742-750. | 1.4 | 3 |
| 47 | Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics. <i>Journal of AIDS & Clinical Research</i> , 2013, 01, . | 0.5 | 16 |
| 48 | An alternative method for quantifying coronary artery calcification: the multi-ethnic study of atherosclerosis (MESA). <i>BMC Medical Imaging</i> , 2012, 12, 14. | 2.7 | 19 |
| 49 | Coronary Calcium Coverage Score: Determination, Correlates, and Predictive Accuracy in the Multi-Ethnic Study of Atherosclerosis. <i>Radiology</i> , 2008, 247, 669-675. | 7.3 | 93 |